Pimavanserin + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Conditions
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Trial Timeline
May 21, 2018 → May 6, 2022
NCT ID
NCT03575052About Pimavanserin + Placebo
Pimavanserin + Placebo is a phase 3 stage product being developed by Acadia Pharmaceuticals for Neuropsychiatric Symptoms Related to Neurodegenerative Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03575052. Target conditions include Neuropsychiatric Symptoms Related to Neurodegenerative Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05523895 | Phase 2/3 | Completed |
| NCT04531982 | Phase 3 | Completed |
| NCT03968159 | Phase 3 | Completed |
| NCT03575052 | Phase 3 | Completed |
| NCT02970305 | Phase 2 | Completed |
| NCT02970292 | Phase 3 | Completed |
Competing Products
2 competing products in Neuropsychiatric Symptoms Related to Neurodegenerative Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Cannabidiol Oral Solution [Epidiolex] | Jazz Pharmaceuticals | Approved | 82 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 3 | 72 |